REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients

REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.

FDA advisors to weigh use of Rexulti for Alzheimer's agitation

FDA panel backs approval of Rexulti for Alzheimer's-related agitation

These highlights do not include all the information needed to use

FDA Approves Rexulti For Agitation Associated With Dementia Due To

Otsuka and Lundbeck Issue Statement on FDA Advisory Committee

REXULTI® (brexpiprazole) For Healthcare Professionals

REXULTI® (brexpiprazole) Agitation associated with dementia due

New Drug to Combat Common Problem in Alzheimer's Patients - Fisher

Pyrls on Instagram: Brexpiprazole's (REXULTI) new indication

Dementia: FDA fast-tracks approval for antipsychotic drug Rexulti

FDA Approves First-Ever Drug for Agitation Associated with